RECRUITINGINTERVENTIONAL

Intraindividual Comparison of EMO IOLs

Comparison of Visual Outcomes of Enhanced Monofocal Intraocular Lenses

About This Trial

The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved investigational plan.

Who May Be Eligible (Plain English)

Who May Qualify: - Bilateral age-related cataract planned for phacoemulsification extraction and posterior IOL implantation - Age 50 to 100 - Visual potential in both eyes of 20/25 or better as determined by investigators estimation - Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant - Irregular Astigmatism (Acrysof IQ Vivity IOL, IC-8 Apthera IOL) - postoperativ binocular best corrected distance visual acuity (BCVA) ≥ 1.0 decimal (Arm ten (X)) - Standard cataract surgery with bilateral implantation of a monofocal IOL (Vivinex XC1 or Vivinex XY1) (Arm ten (X)) Who Should NOT Join This Trial: - Preceding intraocular surgery or ocular trauma - Relevant other ophthalmic diseases that particularly effects the zonular apparatus (such as severe pseudoexfoliation syndrome, preceding cryocoagulation, trauma) - Pupil diameter \< 2.0 mm (photopic) - Laser treatment - Uncontrolled systemic or ocular disease - Pregnancy/Nursing - childbearing ability Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Bilateral age-related cataract planned for phacoemulsification extraction and posterior IOL implantation * Age 50 to 100 * Visual potential in both eyes of 20/25 or better as determined by investigators estimation * Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * Irregular Astigmatism (Acrysof IQ Vivity IOL, IC-8 Apthera IOL) * postoperativ binocular best corrected distance visual acuity (BCVA) ≥ 1.0 decimal (Arm ten (X)) * Standard cataract surgery with bilateral implantation of a monofocal IOL (Vivinex XC1 or Vivinex XY1) (Arm ten (X)) Exclusion Criteria: * Preceding intraocular surgery or ocular trauma * Relevant other ophthalmic diseases that particularly effects the zonular apparatus (such as severe pseudoexfoliation syndrome, preceding cryocoagulation, trauma) * Pupil diameter \< 2.0 mm (photopic) * Laser treatment * Uncontrolled systemic or ocular disease * Pregnancy/Nursing * childbearing ability

Treatments Being Tested

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes

PROCEDURE

phacoemulsification and intraocular lens implantation

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (EnVista) vs. an enhanced monofocal IOL (EnVista Aspire)

PROCEDURE

phacoemulsification and intraocular lens implantation

bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced depth of focus IOL (PureSee) in both eyes

PROCEDURE

phacoemulsification and intraocular lens implantation

Locations (1)

Medical University of Vienna

Vienna, Austria